Evidence check: Longevity DNA Test in the context of Wechseljahre

A 'Longevity DNA Test' often claims to predict lifespan or aging based on single SNPs (e.g., FTO, APOE, IL6). In the context of menopause, the evidence is weak: hormonal shifts (estrogen decline) have a far greater impact on metabolism, bone health, and cardiovascular risk than most tested variants. The provided context lacks any specific studies on longevity tests during menopause. While some GWAS associations exist (e.g., IL6 for inflammation), effect sizes are small and not deterministic. Such a test cannot replace a personalized menopause strategy. Evidence-based approaches—adequate calcium/vitamin D, resistance training, stress management, and possibly hormone therapy under medical guidance—are more effective. Therefore, the evidence level is 'marketing': there is no solid scientific basis for specific recommendations in menopause from these tests.